RSV vaccine tested in younger, At-Risk adults shows promise

NCT ID NCT06389487

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study tested an investigational RSV vaccine in adults aged 18-49 who have chronic health conditions that put them at higher risk for severe RSV illness. Researchers compared the vaccine's safety and the immune response it triggered in these younger adults to the response in adults aged 60 and older. The goal was to see if the vaccine worked as well for the younger, at-risk group.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Glendale, Arizona, 85308, United States
GSK Investigational Site

Phoenix, Arizona, 85284, United States
GSK Investigational Site

North Hollywood, California, 91606-3287, United States
GSK Investigational Site

Oakland, California, 94610, United States
GSK Investigational Site

Walnut Creek, California, 94598, United States
GSK Investigational Site

Hialeah, Florida, 33012, United States
GSK Investigational Site

North Miami, Florida, 33173, United States
GSK Investigational Site

Orlando, Florida, 32806, United States
GSK Investigational Site

Lexington, Kentucky, 40509, United States
GSK Investigational Site

Silver Spring, Maryland, 20904, United States
GSK Investigational Site

Rochester, New York, 14609, United States
GSK Investigational Site

Oklahoma City, Oklahoma, 73111, United States
GSK Investigational Site

Knoxville, Tennessee, 37909, United States
GSK Investigational Site

DeSoto, Texas, 75115, United States
GSK Investigational Site

Charlottesville, Virginia, 22911, United States
GSK Investigational Site

Wenatchee, Washington, 98801, United States
GSK Investigational Site

Coffs Harbour, New South Wales, 2450, Australia
GSK Investigational Site

Sydney, New South Wales, 2010, Australia
GSK Investigational Site

Sydney, New South Wales, 2065, Australia
GSK Investigational Site

Fortitude Valley, Queensland, 4006, Australia
GSK Investigational Site

Tarragindi, Queensland, 4121, Australia
GSK Investigational Site

Melbourne, Victoria, 3051, Australia
GSK Investigational Site

St Albans, Victoria, 3021, Australia
GSK Investigational Site

New Westminster, British Columbia, V3L 3W4, Canada
GSK Investigational Site

Victoria, British Columbia, V8V 4A1, Canada
GSK Investigational Site

Truro, Nova Scotia, B2N 1L2, Canada
GSK Investigational Site

Greater Sudbury, Ontario, P3C 1X3, Canada
GSK Investigational Site

Guelph, Ontario, N1G 0B4, Canada
GSK Investigational Site

London-Ontario, Ontario, N5W 6A2, Canada
GSK Investigational Site

Toronto, Ontario, M4G 3E8, Canada
GSK Investigational Site

Québec, Quebec, G1N 4V3, Canada
GSK Investigational Site

Québec, Quebec, G1V 4G2, Canada
GSK Investigational Site

Québec, Quebec, G1V 4W2, Canada
GSK Investigational Site

Saint-Charles-Borromée, Quebec, J6E 2B4, Canada
GSK Investigational Site

Sherbrooke, Quebec, J1J 2G2, Canada
GSK Investigational Site

Weinheim, Baden-Wurttemberg, 69469, Germany
GSK Investigational Site

Berlin, 10117, Germany
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Berlin, 13347, Germany
GSK Investigational Site

Essen, 45355, Germany
GSK Investigational Site

Mainz, 55116, Germany
GSK Investigational Site

Wallerfing, 94574, Germany
GSK Investigational Site

Witten, 58455, Germany
GSK Investigational Site

Würzburg, 97070, Germany
GSK Investigational Site

Ibaraki, 300-0062, Japan
GSK Investigational Site

Kanagawa, 211-0041, Japan
GSK Investigational Site

Tokyo, 155-0031, Japan
GSK Investigational Site

Tokyo, 180-0022, Japan
GSK Investigational Site

Cape Town, 7530, South Africa
GSK Investigational Site

Cape Town, 7700, South Africa
GSK Investigational Site

Johannesburg, 2113, South Africa
GSK Investigational Site

Reiger Park, 1459, South Africa

Conditions

Explore the condition pages connected to this study.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS